KCNQ Agonist Stability via Nitrogen Substitution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current KCNQ agonists, such as retigabine, are prone to oxidation and have limited brain tissue distribution, affecting their therapeutic efficacy in treating epilepsy and related neurological disorders.
Innovation Solution
Development of novel compounds with specific structural modifications, including substitution patterns on nitrogen atoms, to enhance stability and brain tissue concentration, retaining or increasing the activity of activating potassium ion channels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current KCNQ agonists such as retigabine are used, then potassium ion channels can be activated to decrease neuronal excitability, but the compounds are prone to oxidation and have limited brain tissue distribution
Solution Approach 1:
The patent modifies the chemical structure of KCNQ agonists by changing substitution patterns on nitrogen atoms (e.g., using N-alkyl, N-ary, or N-heteroary groups instead of simple amino groups), which alters the electronic and steric parameters of the molecule. These parameter changes enhance resistance to oxidation while maintaining channel activation capability
Solution Approach 2:
The invention creates composite molecular structures combining the core KCNQ agonist scaffold with various stabilizing substituents (such as electron-withdrawing groups, bulky alkyl groups, or aromatic systems). This composite approach provides both the pharmacological activity and oxidative stability required
2Quantity of substance
If current KCNQ agonists such as retigabine are used, then potassium ion channels can be activated, but the brain tissue distribution is limited affecting therapeutic efficacy
Solution Approach 1:
The patent optimizes lipophilicity (logP), molecular weight, and hydrogen bonding capacity by selecting specific substituents (e.g., alkyl chains of C1-C6, aromatic groups with appropriate substitution patterns). These parameter adjustments enhance blood-brain barrier penetration and brain tissue distribution while preserving KCNQ channel activation
Solution Approach 2:
Instead of trying to increase brain concentration by increasing dose (which would increase systemic exposure and side effects), the invention inverts the approach by modifying molecular properties to selectively enhance brain tissue uptake and retention, achieving higher effective concentration at the target site without proportionally increasing plasma levels
3Reliability
If structural modifications are made to enhance stability and brain tissue distribution, then therapeutic outcomes improve, but compound complexity increases
Solution Approach 1:
The patent introduces complexity only at specific locations on the molecule (e.g., substitution at the para-position of the benzene ring, or modification of one specific nitrogen atom) rather than throughout the entire structure. This localized approach provides the necessary stability and distribution improvements while minimizing overall molecular complexity
Solution Approach 2:
The invention systematically varies substitution patterns (ortho, meta, para positions), chain lengths (C1-C6 alkyl), and aromatic/heteroary groups in a controlled manner. This parameter optimization achieves therapeutic goals while maintaining reasonable structural simplicity for synthesis and characterization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel compounds exhibit improved stability, higher brain tissue distribution, and significant anti-epileptic effects, offering better therapeutic outcomes compared to existing KCNQ agonists.
Implementation Method 1
By activating potassium ion channels to decrease neuronal excitability, such agonists of potassium ion channels not only can be used in treatment of epilepsy but also can be used in treatment of other diseases induced by exorbitant neuronal excitability
Data Source
AI summary
The present invention provides compounds having the structure represented by general formula I, pharmaceutically acceptable salts thereofagonist, preparation methods therefor and a use thereof in the preparation of a medcine for the treatment of nervous system diseases. The compounds or pharmaceutical compositions thereof can be used as the KCNQ potassium channel agonist for treating nervous system diseases. Compared to retigabine, a compound in the prior art, the compound of the present invention have the same or better therapeutic effect, are easier for synthesis and storage, and less prone to oxidate deterioration.